(Updated - March 14, 2024 3:52 PM EDT)

Madrigal Pharma (NASDAQ: MDGL): FDA Approves rezdiffra - website.

• Rezdiffra indicated in conjunction with diet, exercise for treatment of adults with NASH with moderate to advanced liver fibrosis.
  

Corporate News FDA Hot FDA News

Madrigal Pharmaceuticals (MDGL) PT Raised to $425 at H.C. Wainwright, 'Rezdiffra Achieves Landmark Approval'March 15, 2024 6:11 AM Madrigal Pharmaceuticals (MDGL) PT Raised to $389 at CitiMarch 15, 2024 3:49 AM Madrigal Pharma (MDGL) Confirms FDA Approval of Rezdiffra for Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver FibrosisMarch 14, 2024 4:16 PM